Dechra Pharmaceuticals PLC Directorate Change (0995U)
31 Marzo 2021 - 10:00AM
UK Regulatory
TIDMDPH
RNS Number : 0995U
Dechra Pharmaceuticals PLC
31 March 2021
31 March 2021
Dechra(R) Pharmaceuticals PLC
(Dechra, the Company or the Group)
Appointment of Denise Goode as Non-Executive Director of Dechra
Pharmaceuticals PLC
Dechra is pleased to announce that, with effect from 26 April
2021, Denise Goode will take up a new position as a Non-Executive
Director of the Company. Denise will be a member of the Group's
Audit, Remuneration and Nomination Committees with the intention
that she will be appointed as Chairman of the Audit Committee upon
Julian Heslop's retirement as Audit Committee Chairman following
the 2021 Annual General Meeting.
Denise brings a wealth of financial, commercial and life science
industry experience, both from her extensive career as a senior
executive and from board roles held since 2008. She has a deep
understanding of the pharmaceuticals sector and is highly
experienced in business development.
Denise is currently a Non-Executive Director of Abliva AB, a
NASDAQ Sweden listed company, where she is Chair of the
Remuneration Committee and a member of the Audit Committee. She is
also Vice President, Business Development at AnaMar AB, a Swedish
based private company. In 2014 Denise established QED Life Sciences
Limited, through which as CEO she advises and supports the
strategic direction of biotech companies. Prior to this, Denise was
Chair of the Audit Committee at Oxford Bioscience Network from 2014
to 2017 and of AstraZeneca Ireland Operations Ltd from 2008 to
2013. Over her 20 year global career with AstraZeneca
Pharmaceuticals PLC, Denise held senior leadership roles within the
finance and commercial activities of the global entity. She is a
Fellow of the Institute of Chartered Accountants in England and
Wales.
Commenting on the appointment Tony Rice, Chairman, Dechra
Pharmaceuticals said:
" On behalf of the Board and all stakeholders I am delighted to
welcome Denise to Dechra. She will add significant pharmaceutical
and financial experience and capabilities to the team as well as
providing continuity during the next phase of Dechra's growth and
development."
There are no other disclosures to be made in respect of Denise
Goode, pursuant to Listing Rule 9.6.13R.
Enquiries to:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer
Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director
Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFIFFDVEILVIL
(END) Dow Jones Newswires
March 31, 2021 04:00 ET (08:00 GMT)
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Apr 2023 a Apr 2024